Discover how the biopharma cold chain market is evolving and where new opportunities are emerging.
Our latest industry report dives deep into the trends driving growth, from the rise of temperature-sensitive biologics to the technological advancements reshaping logistics. With a projected 13% annual growth rate, the biopharma cold chain is not just growing—it's transforming.
Learn how strategic investments in packaging, transportation, warehousing, and monitoring can position your company for success in this dynamic landscape. Whether you're a new entrant or an established player, this report provides the insights you need to navigate the complexities and capitalize on the opportunities ahead.
Download the Report
The U.S. Pharma Premium: Who’s Really Paying the Price?
June 30, 2025
For decades, the United States has shouldered a disproportionate share of global pharmaceutical costs, accounting for 70% of global biopharma profits and over 80% of new drug launches. While this has helped drive significant medical innovation and supported the majority of global drug launches, it has also resulted in higher out-of-pocket costs for American patients.
When Security Creates Scarcity: DSCSA’s Unintended Consequence
June 2, 2025
In a recent article, A&M Life Sciences experts discuss The Drug Supply Chain Security Act and how well-intentioned regulations may be straining the very system they’re meant to safeguard.
Medtech CDMOs in 2025: Perspectives on Activity in the Medtech CDMO Market
May 19, 2025
Driving the future of medical innovation, Medtech CDMOs are leveraging strategic M&A and advanced technologies to scale growth. Amid regulatory complexity, key players are accelerating development and meeting rising demand for specialized manufacturing.
Discover the Future of Connected Health
May 2, 2025
Dive into "The Seven Truths of Connected Health," our latest Life Sciences report that explores how connected health changes patient behavior at key decision points.
